Stem cell research and organoid biobanks are creating new opportunities in the India organoids market. These resources can provide standardized biological models for drug discovery, disease research, toxicity testing, and personalized medicine.

The market was valued at approximately USD 84 million in 2024 and is expected to reach about USD 831.13 million by 2035 at a CAGR of 23.17%. Stem cell research, regenerative medicine, and expanding biotechnology infrastructure are important market drivers.

Stem-cell-derived organoids can mimic selected features of organs and tissues. They are being explored for liver, kidney, pancreas, intestine, brain, and other research applications.

Induced pluripotent stem cells are gaining importance because they can be reprogrammed and differentiated into specialized cell types. This supports disease modeling, patient-specific research, and regenerative medicine.

Organoid biobanks can store and distribute standardized models for research institutions, pharmaceutical companies, and CROs. They may improve reproducibility and reduce the time required to establish experimental models.

Academic institutions are major contributors to stem-cell and organoid research. Biotechnology companies and pharmaceutical organizations are increasingly partnering with universities and hospitals.

Key players include TissUse, InSphero, Mimetas, Organovo, STEMCELL Technologies, Corning, Cytiva, Sartorius, Lonza, and Crown Bioscience.

Read more: India Organoids Market Size, Growth Report

People Also Ask

Q1. Why are stem cells important for organoid research?
Stem cells can generate specialized tissue models and support disease research, regenerative medicine, and patient-specific studies.

Q2. What is an organoid biobank?
It is a collection of stored organoid models used by researchers and companies for standardized testing and experimentation.

Tags: stem-cell organoids, organoid biobank, regenerative medicine, iPSC organoids, India biotechnology